Casirivimab and Imdevimab, Repeat Doses, Home or Residence

Name: Negotiated commercial rates for Casirivimab and Imdevimab, Repeat Doses, Home or Residence (HCPCS M0241), in Wyoming
Creator: Tynbil
License: https://tynbil.com/terms

Wyoming rates for HCPCS M0241

Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses

Rates data updated July 2026.

Rates by insurance carrier

Insurance Carrier	Facility/Professional	Modifier	Typical Low	Median	Typical High